Dear Mr. Votzmeyer:

Please refer to your supplemental new drug applications dated June 19, 2006, received June 20, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for KALETRA®, (80 mg Lopinavir/20 mg Ritonavir) Oral Solution and KALETRA®, (200 mg Lopinavir/50 mg Ritonavir) Tablets.

We acknowledge receipt of your submissions dated February 6, 2007 and April 2, 2007.

These supplemental new drug applications provide for the use of KALETRA® (Lopinavir/Ritonavir) tablets and oral solution in combination with other antiretroviral agents for the treatment of HIV infection.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text. The approval was based on review of one phase 2 trial (M97-720) used to support long-term (Week 360) efficacy and safety data.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and text for the patient package insert).

Please submit an electronic version of the FPL according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate these submissions “FPL for approved supplement NDA 21-251/S-012 and NDA 21-906/S-002.” Approval of these submissions by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and
effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are deferring submission of your pediatric studies for neonates to < 6 months and adolescents from 12 years to 16 years until June 30, 2007.

Your deferred pediatric studies required under section 2 of the Pediatric Research Equity Act (PREA) are considered required postmarketing study commitments. The status of these postmarketing studies shall be reported annually according to 21 CFR 314.81. These commitments are listed below.

1. Multiple-dose pharmacokinetics, safety and activity study of ABT-378/ritonavir in combination with other antiretroviral agents in HIV-infected pediatric patients

   Submission date: June 30, 2007


   Submission date: June 30, 2007

We also remind you of additional post-marketing commitments outlined in the January 18, 2002, and October 28, 2005 approval letters.

Submit final study reports to the NDA. For administrative purposes, all submissions related to pediatric postmarketing study commitments must be clearly designated “**Required Pediatric Study Commitments**”.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to these NDAs and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Karen Winestock, Regulatory Project Manager, at (301) 796-0834.

Sincerely,

(See appended electronic signature page)

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosures: Package Insert and Patient Package Insert
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Jeffrey Murray
4/20/2007 10:51:03 AM
for D. Birnkrant